TY - JOUR
T1 - Utility of LRF/pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant hodgkin lymphoma and classical hodgkin lymphoma
AU - Bohn, Olga
AU - Maeda, Takahiro
AU - Filatov, Alexander
AU - Lunardi, Andrea
AU - Pandolfi, Pier Paolo
AU - Teruya-Feldstein, Julie
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by National Institutes of Health/National Cancer Institute funding awarded to PPP (RO1 CA102142) and the Department of Pathology, Memorial Sloan-Kettering Cancer Center.
PY - 2014/2
Y1 - 2014/2
N2 - Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) are considered separate entities with different prognosis and treatment. However, morphologic features can be similar and immunohistochemical studies are essential in the distinction; thus, determination of additional biomarkers is of utmost importance. LRF/Pokemon is a proto-oncogene, an interacting partner co-expressed with BCL6 in germinal centers and highly expressed in diffuse large B-cell lymphoma and follicular lymphoma. Conversely, loss of the LRF gene in mouse hematopoietic stem cells results in complete block of early B cell development with concomitant Notch de-repression, indicating its critical role in B versus T cell fate decision at the hematopoietic stem cell stage. For the first time, we show that LRF/Pokemon is predominantly expressed in NLPHL cases as is BCL6 with low to absent NOTCH1 protein expression; while Hodgkin Reed-Sternberg (HRS) cells in CHL show low to absent BCL6 and LRF/Pokemon expression with higher NOTCH1 expression. We illustrate a potential functional interaction between LRF and BCL6 in NLPHL pathogenesis, and differential expression of LRF/Pokemon and NOTCH1 proteins in CHL thus showing differential expression, making for an additional diagnostic marker and therapeutic target.
AB - Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) are considered separate entities with different prognosis and treatment. However, morphologic features can be similar and immunohistochemical studies are essential in the distinction; thus, determination of additional biomarkers is of utmost importance. LRF/Pokemon is a proto-oncogene, an interacting partner co-expressed with BCL6 in germinal centers and highly expressed in diffuse large B-cell lymphoma and follicular lymphoma. Conversely, loss of the LRF gene in mouse hematopoietic stem cells results in complete block of early B cell development with concomitant Notch de-repression, indicating its critical role in B versus T cell fate decision at the hematopoietic stem cell stage. For the first time, we show that LRF/Pokemon is predominantly expressed in NLPHL cases as is BCL6 with low to absent NOTCH1 protein expression; while Hodgkin Reed-Sternberg (HRS) cells in CHL show low to absent BCL6 and LRF/Pokemon expression with higher NOTCH1 expression. We illustrate a potential functional interaction between LRF and BCL6 in NLPHL pathogenesis, and differential expression of LRF/Pokemon and NOTCH1 proteins in CHL thus showing differential expression, making for an additional diagnostic marker and therapeutic target.
KW - Hodgkin lymphoma
KW - LRF
KW - Pokemon
KW - classical Hodgkin lymphoma (cHL)
KW - nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
UR - http://www.scopus.com/inward/record.url?scp=84893616003&partnerID=8YFLogxK
U2 - 10.1177/1066896913513833
DO - 10.1177/1066896913513833
M3 - Article
C2 - 24326827
AN - SCOPUS:84893616003
VL - 22
SP - 6
EP - 11
JO - International Journal of Surgical Pathology
JF - International Journal of Surgical Pathology
SN - 1066-8969
IS - 1
ER -